Online inquiry

IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6050MR)

This product GTTS-WQ6050MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Giant cell arteritis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6050MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9909MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ755MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ225MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ15171MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ2599MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ7539MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ4923MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ15464MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA U3-1287
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW